COVID-19 test eligible for WHO Emergency Use Listing

Paris, France and Camberley, UK – 8 April 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that its test for COVID-19 (Z-Path COVID-19-CE IVD) has been listed as eligible for World Health Organization (WHO) procurement under the WHO Emergency Use Listing (EUL) process. The test will be eligible for procurement for one year, unless circumstances dictate otherwise. The test has been developed by Novacyt’s molecular diagnostics division, Primerdesign, based in Southampton, UK.